Incyte

Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
Zai builds cancer combo strategy with rights to Incyte's PD-1 mAb
BioCentury
Zai Lab
China
PD-1 inhibitors
Incyte
Flag link:
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Fierce Pharma
Eli Lilly
Incyte
olumiant
safety data
Humira
rheumatoid arthritis
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
Yahoo/Benzinga
ADA
Merck
Keytruda
NGM Biopharmaceuticals
NGM313/MK-3655
Corbus Pharmaceuticals
Nektar
Galapagos
Kezar Life Sciences
Kura Oncology
Bluebird Bio
BeiGene
Global Blood Therapeutics
Blueprint Medicines
Regeneron
Arqule
Sunesis
Sutro BioPharma
Incyte
Geron
Forty Seven
Flag link:
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
#ASCO19: MET inhibitors from Incyte/Novartis and Germany's Merck face off for rare subset of NSCLC patients
Endpoints
Novartis
ASCO 2019
Incyte
MET inhibitors
capmatinib
non-small cell lung cancer
Flag link:
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi
Yahoo/Zacks.com
FDA
Incyte
Jakafi
graft vs host disease
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Incyte
Novartis
Athersys
ResTORbio
Bellerophon Therapeutics
Eli Lilly
CymaBay
Bicycle Therapeutics
Peloton Therapeutics
Ideaya
IPOs
Flag link:
Biotech Companies Provide High Median Salaries, Analysis Shows
Biotech Companies Provide High Median Salaries, Analysis Shows
BioSpace
salaries
biotech
Incyte
Celgene
Vertex Pharmaceuticals
Flag link:
Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline
Incyte pulls away 'damaged goods' baricitinib to focus on internal pipeline
Endpoints
Incyte
olumiant
baricitinib
FDA
Eli Lilly
Flag link:
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Incyte Down as FDA Extends Review Period of Jakafi for GVHD
Yahoo/Zacks.com
Incyte
FDA
Jakafi
graft vs host disease
Flag link:
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
Lilly and Incyte's Olumiant Hits the Mark in Two Phase III Atopic Dermatitis Trials
BioSpace
Eli Lilly
Incyte
olumiant
atopic dermatitis
clinical trials
Flag link:
Mark Your Calendar For These February PDUFA Dates
Mark Your Calendar For These February PDUFA Dates
Yahoo/Benzinga
FDA
DWP-450
Evolus
MOTIF BIO PLC/S ADR
Iclaprim
Bausch Health
Duobrii
Merck
Keytruda
Incyte
Novartis
ruxolitinib
Novo Nordisk
N8-GP
Flag link:
Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
Why Yet Another Biotech Stock Is Grabbing Renewed Takeover Chatter
Investors Business Daily
Incyte
M&A
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
Innovent, Incyte sign collaboration deal for three clinical-stage product candidates
Innovent, Incyte sign collaboration deal for three clinical-stage product candidates
Pharmaceutical Business Review
Incyte
Innovent Biologics
pemigatinib
itacitinib
parsaclisib
Flag link:
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Yahoo/Zacks.com
M&A
Biomarin
Vertex Pharmaceuticals
Incyte
Alnylam
Alexion
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
FDA
Incyte
Novartis
Jakavi
Jakafi
graft vs host disease
Flag link:
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
Incyte
graft vs host disease
Novartis
Jakafi
Flag link:
Agenus sells cut of Incyte, Merck milestone streams
Agenus sells cut of Incyte, Merck milestone streams
Fierce Biotech
Agenus
Incyte
Merck
Xoma
Flag link:
Incyte preps Jakafi expansion into graft-versus-host disease
Incyte preps Jakafi expansion into graft-versus-host disease
Biopharma Dive
Incyte
Jakafi
graft vs host disease
Flag link:
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Eli Lilly’s Arthritis Drug Approved at Lower Dose with Boxed Warning
Xconomy
Eli Lilly
Incyte
FDA
rheumatoid arthritis
olumiant
baricitinib
Flag link:

Pages